Clinical trial
Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes
NCT04774445 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Phase
- Not applicable
- Overall status
- Active, not recruiting
- Start date
- May 3, 2021
- Completion date
- April 1, 2026
- Enrollment
- 400 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cancer, genetic predisposition